Biofrontera Inc. — Third Quarter 2026 Earnings Summary

Biofrontera Inc. reported net product revenue of $9.1 million for the third quarter of 2026, representing a 29.8% increase from the prior-year period. The company achieved a gross margin of 74.4% and a net loss of $6.4 million, or $0.42 per share, during the quarter. Key developments included FDA approval of Ameluz for superficial basal cell carcinoma and a U.S. Customs ruling allowing the import of the redesigned XL-C lamp. For the nine months ended September 30, 2026, revenue grew 26.6% to $31.2 million while the net loss narrowed to $11.8 million.